Narrow Results

India’s Nath Seeds Ties up with Chinese Biotech Firm for Bt Cotton.

Japan’s Takara Grants Molmed Right to Use RetroNectin for Gene Therapy.

Sumitomo to Access LifeSpan’s GPCR Expression and Localization Database.

Wyeth Lederle Japan Transfers Over-the-counter Drugs to Takeda.

Kyowa Hakko Develops New Antibody Technology.

Australia’s BTF Completes Prototype for Precise Culture Based Microorganisms.

Novogen to Start Phenoxodiol Clinical Trials in Australia.

China Investigates Fault in US-made Tempo Pacemakers.

Japan Drugmakers to Boost Sales in China.

YuHan at Forefront of Pharmaceuticals in Korea.

Eli Lilly Opens Asian Headquarters in Hong Kong.

DSM Produces Semi-synthetic Penicillin in China.

World Diagnostics to Sell Test Kits in India and Vietnam.

AMDL Reports Disappointing Sales from Asian Distributor.

Taiwan University and AbGenomics to Develop Proprietary Biomedical Platforms.

Omeros Medical Systems and Singapore Institute to Develop New Drug Delivery System.

The article summarises Asia as a biotechnology hub focusing on Singapore, Taiwan, Malaysia, India, Japan, China, Hong Kong, South Korea, Sri Lanka and Thailand. It describes how Asia is one of the more attractive locations for global biotechnology companies to invest in highly skilled staff and world class technologies.

This article deals about the Government Perspective on the Life Science in Taiwan.

New President Elected to Helm ABLE.

DIA appoints Chair of Regional Advisory Council, Japan.

New Leadership Appointments of A*STAR to Drive Research Innovation.

Biotech Crops Catch On in Brazil.

China Biologic Products Appoints New Directors.

Pfizer Research Unit Moves to China.

First China to Acquire Shenzhen Ming He Tang.

Novartis to Recover Growth in China.

India Enthusiastic to Export Pharmas to China.

Indian Pharma Wants Nigeria to Abolish Drug Inspection.

Innovative Approach to Rare Disease Research by Max Neeman.

SG Biofuels Expands into India.

Karo Bio & Zydus Extend Research Collaboration.

QPS Acquires Qualitix.

GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology

NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStem's Licensed Orthopedic Technology

BGI and TTI GG Initiate 100 Tomato Genome Project

Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership

Merck & Co., Inc., and Sun Pharma Sign JV for Medicines in Emerging Markets

Sosei Acquires Development and Commercialization Rights to Loramyc(R) from BioAlliance Pharma

ICON and ACRONET Sign Alliance Agreement in Japan

Takeda and Samyang Form Research Collaboration in Novel DDS Platform Technology for RNAi Therapeutics

A*STAR Scientists Partner French Pharma to Develop Anti-Cancer Drugs That Nip Breast Cancer In The Bud

China to Cease Harvesting Inmate Organs.

China Needs More Than 20 Years to Catch Up on Innovation.

Roads to Design an Efficient Non-viral Gene Delivery System.

Rice MADS29 Transcription Factor Regulates Seed Development.

Vermont Benefits From BioTek's China Focus.

Healthcare Reforms Squeezing China Pharmaceuticals.

2011 Watershed Year for Chinese Life Science.

Novasep Opens New Shanghai Facilities.

Institute of Biological Chemistry researchers find new protein-DNA interaction.

Medicago to receive up to US$12 million.

INEX inks partnership with BGI for new non-invasive prenatal test.

China emerging as 'major player' for pharmaceuticals.

Possible cure for dementia found by Taiwan researchers.

BGI@CHOP Joint Genome Center to offer clinical next-generation sequencing services.

Biologists at Academia Sinica develops a new molecular strategy to suppress Hepatitis C virus replication.

Molecular cloning, characterization, and expression analysis of genes encoding Gibberellin 20-Oxidase in Dasypyrumvillosum dwarf mutant.

Toxicity of Engineered Nanomaterials.

2013 – A Year of Access, Convergence and Technology.

Cancer Targeting Nanomedicine: An Opportunity for Drug Development in Asia with Emphasis on Taiwan.

ASEAN Economic Community 2015: Opportunities for Trade and Investment in Thailand's Biotechnology Sector.

Quality Issues in Pharmaceuticals: An Overview into Root Cause Investigations.

Hospitals' Community Benefits: A Measure of Social Responsibility in Health Care.

Journey to the East: The growing Role of Asian Headquarters for Multinational Life Sciences Companies.

Therapy for Hippocampus Injury: Can Neural Stem Cells Help?

Nanject: Drug Delivery Cancer Cells Detection.

Science Communication: Singapore Science Centre Style.

The future of pharma: Digital, personalized, and dynamic.

Using real world evidence in the development of new medicine.

Hunting for new drugs to treat mental illness.

Clean cow starts now.

During the past 20 years, supercritical fluid (SCF) based technologies have been gaining an increasing attention through the academic and industrial communities due to its advantages. One of the most important parameter for any supercritical-based technologies is the knowledge of the solute solubility at different pressures and temperatures. But, due to several concerns e.g. time and expense, measuring the solubility of all compounds in wide ranges of temperature and pressure is not possible. Respect to this, a new empirical correlation with four fitting parameters has been proposed to correlate the solubility of pharmaceuticals in different temperatures and pressures. The obtained results compared with four widely used density based correlations including Mendez-Santiago and Teja (MST), Bartle et al., Chrastil, Kumar and Johnston (KJ) revealed rather good capability of the proposed simple correlation for predicting the solubility of solutes in supercritical carbon dioxide (SC-CO₂). At last, the obtained results compared with the results of three Equations of State (EoS's) with three different mixing rules.

Multiple interacting factors influence the uptake and diffusion of medicines which are critical to improving health. However, there is a gap in our knowledge on how regulatory policies and other national health systems attributes combine to impact on the utilisation of innovative drugs, and health system goals and objectives.

Our review demonstrates that strong regulation adversely affects, access to innovation, reduces incentives for research-based firms to develop innovative products and leads to short- and long-term welfare losses. Short-term efficiency gains from reducing pharmaceutical expenditures may actually increase total healthcare costs, reduce user choice, and in some cases, adversely affect health outcomes.

Decision makers need to adopt a holistic approach to policy making, and consider potential impact of regulations on the uptake and diffusion of innovations, innovation systems and health system goals.

Organisations engage in various activities designed to foster effective learning. Three forms of learning with important implications for the innovation process are experiential (whereby firms gain relevant insights through direct experience with patterns of action), vicarious (observation of external activities, with inference and other attributions being employed to reconstruct the underlying processes) and inter-organisational (direct contact with outside entities). This paper examines the influence of these forms of learning throughout the process of technological innovation. Using interview and archival data from 11 innovation projects in biopharmaceuticals and medical devices, I uncover evidence of three distinct learning sequences: (1) intensive-externalising (IE); (2) intensive-internalising (II); and (3) expansive-internalising (EI). The sequences vary both in the breadth of learning forms utilised and in the degree to which resultant knowledge is internalised as subsequent innovations are pursued. These findings offer useful insights into the locus and sources of learning for innovation processes in technologically complex settings.

This paper considers the timing of issuing a compulsory license on pharmaceuticals. Apart from confirming the role of basic public health concerns--such as the virulence and prevalence of the disease to be addressed--in compulsory licensing, the paper identifies key economic variables of direct concern to a revenue-maximizing government with the power to issue the license. The paper finds that a disease that threatens to reduce domestic tax revenues is likely to be met with a move toward generic manufacturing of patented drugs. A compulsory license is less likely to be issued if retaliation by trade partners endangers the domestic export sector or if foreign trade contributes significantly to government finances. Thailand’s 2006 compulsory license issue is discussed as an example supporting the implications derived from the model.

Commentary on the Doha Development Round from a representative of Merck.

Thomas Bombelles is Director, International Government Relations, for Merck & Co., Inc. His responsibilities include definition and advocacy on important international business and policy issues for the company focusing on government agencies and other institutions in Washington, DC. Prior to joining Merck, Bombelles was the Assistant Vice President International at the Pharmaceutical Research and Manufacturers of America (PhRMA), the professional association representing the American research-based pharmaceutical industry globally. He has also worked as a private sector consultant, as a trade analyst in the Department of Commerce, and in the US Congress. He received an M.A. degree from the Paul H. Nitze School of Advanced International Studies at Johns Hopkins University, and a B.A. degree from the honors program at the University of Michigan, Ann Arbor.

The aim of this chapter is to explore the stakes at play in relation to the proposed COVID-19 IP waiver, assess what other factors affect access to COVID-19 vaccines, diagnostics, and therapeutics worldwide, and briefly discuss initiatives taken at different levels to improve access to countries lagging behind. With 458 million cases of COVID-19 diagnosed worldwide and more than 6 million deaths by March 2022, the question is whether lifting intellectual property rights (IPRs) restrictions is the solution to unlock the sanitary crisis in developing countries. Policymakers need to be attentive to the impact and role of patents as incentive mechanism and be open to address patent system reforms, but attention should also be paid to IP-related voluntary initiatives and the advantages conferred by other factors, such as first mover advantages, reliance on prior scientific advances, market exclusivity provided by regulatory approvals, advanced purchase agreements, “vaccine nationalism,” data exclusivity from clinical trials, and know-how protected by secrecy. A global approach and more empirical evidence are needed to address the inequalities derived from this pandemic in order to be prepared for the next.

With the COVID-19 pandemic, governments around the globe discovered the vulnerability of the pharma supply chains (PSCs). In this review, we describe the nature of disruptions that occurred and the political debates. Then, we examine some features of the demand in pharmaceuticals: the evolution of the health market, drug supply shortages, and the access to essential medicines. After some reminders about the organization of the pharmaceutical industry and drug manufacturing, we analyze the characteristics of the supply of pharmaceuticals and the trends of the pharma globalization value chain (GVC). Finally, we discuss policy proposals to circumvent the disruption of PSCs in times of crisis, including stockpiling, improving the resilience of the PSCs, protecting the industrial commons, and relocating manufacturing plants. In conclusion, we draw a research agenda for economists and a political agenda for governments.

Multiple interacting factors influence the uptake and diffusion of medicines which are critical to improving health. However, there is a gap in our knowledge on how regulatory policies and other national health systems attributes combine to impact on the utilisation of innovative drugs, and health system goals and objectives.

Our review demonstrates that strong regulation adversely affects access to innovation, reduces incentives for research-based firms to develop innovative products and leads to short- and long-term welfare losses. Short-term efficiency gains from reducing pharmaceutical expenditures may actually increase total healthcare costs, reduce user choice, and in some cases, adversely affect health outcomes.

Decision makers need to adopt a holistic approach to policy making, and consider potential impact of regulations on the uptake and diffusion of innovations, innovation systems and health system goals.

Multi-objective optimization (MOO) has received considerable attention from researchers in chemical engineering. Bhaskar et al. (2000a) have reviewed reported applications of MOO in chemical engineering until 2000. In this chapter, nearly hundred MOO applications in chemical engineering reported in journals from 2000 until mid 2007 are reviewed briefly. These are categorized into five groups: (1) process design and operation, (2) biotechnology and food industry, (3) petroleum refining and petrochemicals, (4) pharmaceuticals and other products/processes, and (5) polymerization. However, applications reported in this book are not included in this review.

Multi-objective optimization (MOO) has received considerable attention from researchers in chemical engineering. Bhaskar et al. (2000a) have reviewed reported applications of MOO in chemical engineering until 2000. In this chapter, nearly hundred MOO applications in chemical engineering reported in journals from 2000 until mid 2007 are reviewed briefly. These are categorized into five groups: (1) process design and operation, (2) biotechnology and food industry, (3) petroleum refining and petrochemicals, (4) pharmaceuticals and other products/processes, and (5) polymerization. Applications reported in this book are not included in this review.